Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

GNOM

Global X Genomics & Biotechnology ETF (GNOM)

Rating:61Neutral
Price Target:$67.00â–²(8.64% Upside)

GNOM, the Global X Genomics & Biotechnology ETF, has a solid overall rating that reflects a mix of strong growth stories and meaningful financial risks in the genomics and biotech space. Higher-quality holdings like Vertex Pharmaceuticals, Qiagen, Illumina, and Natera support the fund’s rating through robust financial performance, positive earnings sentiment, and strong technical momentum, while weaker names such as Twist Bioscience and some loss-making, volatile holdings limit the score due to profitability and valuation concerns. The main risk factor is the fund’s concentration in a single, specialized sector where many companies face ongoing losses, cash flow challenges, and valuation pressures, making it more sensitive to industry downturns.

Positive Factors
Strong Year-to-Date PerformanceThe ETF has delivered strong gains so far this year, showing solid momentum in its genomics and biotech focus.
Leading Biotech HoldingsSeveral of the largest positions, including well-known genomics and biotech companies, have shown strong performance and help drive the fund’s results.
Focused Exposure to Innovative Health CareThe fund’s heavy tilt toward health care and genomics companies gives investors targeted exposure to a fast-growing, innovation-driven area of the market.
Negative Factors
High Sector ConcentrationWith most assets in health care and genomics, the ETF is heavily exposed to swings in a single sector rather than being broadly diversified.
Limited Geographic DiversificationThe portfolio is dominated by U.S. companies, with only a small allocation outside the U.S., which reduces global diversification.
Moderate Expense RatioThe fund’s fees are not especially low, meaning a noticeable portion of returns goes toward covering the ETF’s costs each year.

GNOM vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%SPY+14.55%GNOM+45.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
116.99M
Region
Global
Expense Ratio
0.50%
Beta
1.14
Issuer
Global X
Inception Date
Apr 05, 2019
Dividend Yield
1.05%
Asset Class
Equity
Index Tracked
Solactive Genomics Index

GNOM Summary

GNOM is the Global X Genomics & Biotechnology ETF, which follows the Solactive Genomics Index and focuses on companies using DNA and gene science to improve healthcare. It holds firms working on gene editing, genetic testing, and personalized medicine. Well-known names in the fund include Moderna and Illumina, along with other specialized biotech companies. Someone might invest in GNOM to tap into the long-term growth potential of cutting-edge medical technologies while spreading their money across many genomics stocks. A key risk is that biotech shares can be very volatile, so the ETF’s price can swing sharply up or down.

How much will it cost me?

GNOM has an annual expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 invested. This is higher than the average ETF because it’s a specialized, theme-focused fund in genomics and biotechnology rather than a broad, low-cost index fund.

What would affect this ETF?

GNOM could benefit if breakthroughs in gene editing, sequencing, and personalized medicine drive demand for its global healthcare and biotech holdings like Moderna, Illumina, and Vertex, and if governments and insurers support innovative treatments. On the downside, tighter drug regulations, clinical trial setbacks, changes in healthcare policy, or rising interest rates that make risky growth sectors less attractive could hurt genomics and biotechnology stocks in this ETF.

GNOM Top 10 Holdings

GNOM is a pure play on genomics, with nearly all its firepower aimed at health care innovators rather than broad market names. Moderna has been a key engine lately, rising on renewed optimism around its pipeline, while Illumina and Qiagen provide steadier support as core tools providers to the sequencing world. On the flip side, Twist Bioscience and 10x Genomics have seen more mixed, lagging action, occasionally acting like sandbags on performance despite their long-term promise. With holdings spanning the U.S. and Asia, GNOM offers a global but tightly focused bet on the future of biotech and gene-based medicine.

GNOM top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
MRNAMRNAModerna12.71%$14.87M$90.38B794.91%59Neutral
TWSTTWSTTwist Bioscience5.35%$6.26M$7.35B273.24%43Neutral
TXGTXG10x Genomics5.33%$6.24M$7.65B255.90%60Neutral
GHGHGuardant Health5.28%$6.18M$20.52B61.16%61Neutral
ILMNILMNIllumina4.90%$5.74M$31.30B72.61%71Outperform
NTRANTRANatera4.74%$5.55M$46.27B59.01%73Outperform
HK:1548HK:1548Genscript Biotech3.68%$4.30MHKD 69.04B84.01%60Neutral
QGENQGENQiagen3.83%$4.48M$10.30B6.15%77Outperform
VRTXVRTXVertex Pharmaceuticals3.79%$4.43M$136.56B23.95%78Outperform
TECHTECHBio-Techne3.80%$4.44M$11.44B19.84%64Neutral

GNOM Technical Analysis

Technical Analysis SentimentNegative
Last Price61.67

Price Trends

50DMA66.84Negative
100DMA62.79Negative
200DMA54.55Positive

Market Momentum

MACD-0.91Positive
RSI40.19Neutral
STOCH13.14Positive

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNOM, the sentiment is Negative. The current price of 61.67 is below the 20-day moving average (MA) of 66.91, below the 50-day MA of 66.84, and above the 200-day MA of 54.55, indicating a neutral trend. The MACD of -0.91 indicates Positive momentum. The RSI at 40.19 is Neutral, neither overbought nor oversold. The STOCH value of 13.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNOM.

GNOM Peer Comparison

Comparison Results

GNOM against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
GNOMGNOM$61.67$67.00(8.64% Upside)$116.99M0.50%61Neutral
GIIGII$76.20$82.49(8.25% Upside)$961.94M0.40%62Neutral
BLOKBLOK$49.96$81.98(64.10% Upside)$827.94M0.70%56Neutral
IVESIVES$35.44$52.74(48.80% Upside)$831.44M0.75%70Outperform
ROBTROBT$53.72$72.54(35.04% Upside)$705.39M0.65%61Neutral
IDNAIDNA$40.10$52.44(30.76% Upside)$344.31M0.47%57Neutral

Performance Comparison

0%20%40%60%GNOMGIIBLOKIVESROBTIDNADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GNOM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GNOMGlobal X Genomics & Biotechnology ETF61.6719.0944.82%
GIISPDR S&P Global Infrastructure ETF76.207.7611.34%
BLOKAmplify Transformational Data Sharing Etf49.96-7.74-13.42%
IVESDan IVES Wedbush AI Revolution ETF35.443.7511.83%
ROBTFirst Trust Nasdaq Artificial Intelligence & Robotics ETF53.723.096.11%
IDNAiShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund40.1014.2555.14%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.